In WHO grades II, III, and IV gliomas, RBPS was positively correlated with CD274, CD276, CD80, CD86, CTLA4, FAS, and PDCD1LG2. Finally, to identify potential drugs that targeted RBPS, the potential drugs related to the expression of these six RBP genes were queried in the database, and a correlation analysis was performed. This evidence concerns the gene CD86 and central nervous system cancer.